These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12596012)

  • 21. [Drug-induced myopathies].
    Ando H; Fujimura A
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():390-3. PubMed ID: 18074569
    [No Abstract]   [Full Text] [Related]  

  • 22. Statin-fibrate combination: therapy for hyperlipidemia: a review.
    Wierzbicki AS; Mikhailidis DP; Wray R; Schacter M; Cramb R; Simpson WG; Byrne CB
    Curr Med Res Opin; 2003; 19(3):155-68. PubMed ID: 12814127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
    Caroli-Bosc FX; Le Gall P; Pugliese P; Delabre B; Caroli-Bosc C; Demarquay JF; Delmont JP; Rampal P; Montet JC;
    Dig Dis Sci; 2001 Mar; 46(3):540-4. PubMed ID: 11318529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil.
    Alexandridis G; Pappas GA; Elisaf MS
    Am J Med; 2000 Aug; 109(3):261-2. PubMed ID: 11023440
    [No Abstract]   [Full Text] [Related]  

  • 25. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statin induced myopathy.
    Frank RE
    J Insur Med; 2009; 41(2):132-5. PubMed ID: 19845216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.
    Unal A; Torun E; Sipahioglu MH; Tokgoz B; Kaya MG; Oymak O; Utas C
    Intern Med; 2008; 47(11):1017-9. PubMed ID: 18520113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myopathy due to statin/fibrate use in the Netherlands.
    Mantel-Teeuwisse AK; Klungel OH; Herings RM; van Puijenbroek EP; Porsius AJ; de Boer A
    Ann Pharmacother; 2002 Dec; 36(12):1957-60. PubMed ID: 12452761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
    Milionis H
    Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How well tolerated are lipid-lowering drugs?
    Tomlinson B; Chan P; Lan W
    Drugs Aging; 2001; 18(9):665-83. PubMed ID: 11599634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy.
    Yildiz A; Gucuk E; Cay S
    Acta Cardiol; 2008 Aug; 63(4):515-7. PubMed ID: 18795591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 Apr; 145(16):48-50. PubMed ID: 14606402
    [No Abstract]   [Full Text] [Related]  

  • 34. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Myotoxicity and rhabdomyolisis due to statins].
    Banga JD
    Ned Tijdschr Geneeskd; 2001 Dec; 145(49):2371-6. PubMed ID: 11770264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rhabdomyolysis and lipid-lowering drugs.
    Tenenbaum A; Fisman EZ; Motro M
    JAMA; 2005 Mar; 293(12):1448; author reply 1448-9. PubMed ID: 15784863
    [No Abstract]   [Full Text] [Related]  

  • 37. The safety of statins in clinical practice.
    Armitage J
    Lancet; 2007 Nov; 370(9601):1781-90. PubMed ID: 17559928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Maximal initial dose of simvastatin causing acute renal failure through rhabdomyolysis: risk factors, pathomechanism and therapy related to a case].
    Deme D; Al-Hadad A; Varga T; Szántó E; Sándor K; Rakonczai E
    Orv Hetil; 2009 Feb; 150(6):265-9. PubMed ID: 19179259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk for myopathy with statin therapy in high-risk patients.
    Ballantyne CM; Corsini A; Davidson MH; Holdaas H; Jacobson TA; Leitersdorf E; März W; Reckless JP; Stein EA
    Arch Intern Med; 2003 Mar; 163(5):553-64. PubMed ID: 12622602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.